Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OS Therapies IncOSTX · Entity 6950 | Director | January 22, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OS Therapies Inc
Report date January 22, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2036-01-22 | Direct | 50,000 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 50,000 · Balance 50,000 F1: On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Feb 13, 2026 16:40 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001213900-26-016494 · ownership.xml · derivative · entry 1 Galzahr Karim · CIK 0002055339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date. Read SEC document |
| October 21, 2025 Filed Dec 19, 2025 18:30 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001213900-25-123995 · ownership.xml · derivative · entry 1 Galzahr Karim · CIK 0002055339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-10-21 F1 · derivative.exercise_date: On October 21, 2025, the reporting person was granted options to purchase 140,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.